Fresenius SE KGaA (XTRA:FRE) Expands Biosimilars With WuXi As Undervalued View Holds

What the WuXi Biologics alliance means for Fresenius SE KGaA stock

Fresenius SE KGaA (XTRA:FRE) has just signed an exclusive development agreement with WuXi Biologics that could reshape its biosimilars ambitions and materially expand its Biopharma footprint.

The arrangement opens a route to grow Fresenius' portfolio from 29 marketed and pipeline molecules to as many as 66, addressing originator products with more than €370b in list price based sales.

WuXi Biologics gives the healthcare group access to up to 37 biosimilar candidates over the next decade. Fresenius keeps exclusive global commercialization rights and the full economics of each product selected under the deal.

Management plans to pick individual projects using predefined criteria such as market attractiveness, development risk and expected returns. That selection filter matters because the agreement is described as the largest development partnership announced so far in the biosimilars industry.

The initial focus on polatuzumab vedotin for diffuse large B cell lymphoma and teprotumumab for thyroid eye disease illustrates how the new pipeline reaches beyond Fresenius' existing oncology, immunology and gastroenterology base into neurology, nephrology and cardiopulmonary care.

Development work is expected to rely on WuXi Biologics' global network. Fresenius will then decide over time how manufacturing is organized, including whether to progressively move some monoclonal antibody products to its recently acquired mAbxience platform.

For you as an investor, the key takeaway is that Fresenius is not just adding more product candidates. It is trying to capture a larger share of the value chain from early biosimilar development through to industrial scale production and worldwide commercialization.

Recent trading suggests momentum is building around Fresenius SE KGaA. The share price return over the past month is 11.33% and the 90 day share price return is 9.51%. The three-year total shareholder return of 101.40% signals a much stronger long term rerating than the 1.34% total shareholder return over the last year. The WuXi Biologics agreement is the latest catalyst shaping how investors weigh that track record against the current €48.58 share price.

Compare Fresenius SE KGaA's biosimilar push with other healthcare groups pursuing similar opportunities by screening for 124 healthcare AI stocks, which could be building the next wave of treatment platforms.

After a 101.40% three year total shareholder return and a fresh 11.33% one month move, Fresenius SE KGaA still trades at a discount to both intrinsic estimates and analyst targets. Is the market’s caution misplaced?

Most Popular Narrative: 13% Undervalued

On the most followed view, Fresenius SE KGaA is worth €55.59 a share versus the current €48.58 price. As a result, the WuXi Biologics deal fits into a narrative that already assumes more earnings power ahead.

Fresenius SE KGaA is leaning harder into Kabi growth platforms such as Biopharma, Nutrition and MedTech, which together delivered 12% organic revenue growth and a 17.9% EBIT margin in Q2 2026. Further scaling of these businesses could add to group revenue and earnings power.

See why 36 investors see Fresenius SE KGaA as 13% undervalued.

Result: Fair Value of €55.59 (UNDERVALUED)

Still, two pressure points could quickly challenge that 13% undervalued story for Fresenius SE KGaA: persistent cost inflation and tighter reimbursement or procurement regimes in key markets.

Find out about the key risks to this Fresenius SE KGaA narrative.

Next Steps

Mixed signals on Fresenius SE KGaA so far. If you want to move before the story shifts again, start by weighing the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Fresenius SE KGaA?

If Fresenius SE KGaA has your attention, do not stop there. Use targeted stock lists to pressure test your thinking and uncover alternatives before the crowd moves.

• Target resilient balance sheets and steady fundamentals by reviewing the list of solid balance sheet and fundamentals (196 results).
• Hunt for potential value opportunities by scanning the 194 high quality undervalued stocks.
• Seek future breakout candidates with strong under-the-radar fundamentals by checking the 603 high quality undiscovered gems.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com